Good works: A pair of good neighbors keep finding a way to give money
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
CRE: Oxnard shopping center snatched up by LA investment firm for $90M
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
FDA gives nod to Affinity Biosensors’ flagship product
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Dubroff: Who says The Trade Desk can’t crack the S&P 500
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
CRE: Santa Barbara County DA’s office warns of vacant lot listing scams
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Briq adds another $8 million in extension round
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
A2 Bio’s new CEO aims to grow platform
James Robinson, the new CEO of Agoura Hills-based A2 Biotherapeutics, has several priorities he wants to tackle, not the least of which is to accelerate the company’s proprietary Tmod cell therapy platform. “First principle for us is to maximize the value of the platform that we’ve built,” Robinson, 54, told the Business Times on April Read More →